EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 600 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... July 28, 2021 Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump April 4, 2019 “After a fire and a pandemic, it felt amazing to finish... November 1, 2021 Updated ROAR Analysis Confirms the Benefit of Dabrafenib Plus Trametinib in... January 31, 2022 Load more HOT NEWS Cancer Screening Guidelines Often Lack Information on Potential Harms, Study Finds ΚΑΡΚΙΝΟΣ ΟΥΡΟΔΟΧΟΥ ΚΥΣΤΕΩΣ Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... Bowel Cancer Data Reinforce Need to Reduce Unnecessary Antibiotic Use [ESMO...
